A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence During Pregnancy: Maternal and Neonatal Outcomes

Overview

Journal Subst Abuse

Publisher Sage Publications

Specialty Psychiatry

Date 2013 Mar 28

PMID 23531704

Citations 24

Authors

Ingunn O Lund

Gabriele Fischer

Gabrielle K Welle-Strand

Kevin E OGrady

Kimber Debelak

William R Morrone

Hendree E Jones

Affiliations

Soon will be listed here.

Abstract

Given that buprenorphine + naloxone is prescribed for opioid-dependent pregnant women, it is important to examine the extent to which it differs from buprenorphine alone, methadone, or methadone-assisted withdrawal on neonatal and maternal outcomes. Summary statistics on maternal and neonatal outcomes were collected from 7 previously published studies examining treatment for opioid-dependent pregnant women that represented a range of research methodologies. Outcomes from these studies were compared to the same outcomes for 10 women treated with the combined buprenorphine + naloxone product. There were no significant differences in maternal outcomes for buprenorphine + naloxone compared to buprenorphine, methadone, or methadone-assisted withdrawal. Preliminary findings suggest no significant adverse maternal or neonatal outcomes related to the use of buprenorphine + naloxone for the treatment of opioid dependence during pregnancy. However, further research should examine possible differences between buprenorphine + naloxone and buprenorphine alone or methadone in fetal physical development.

Citing Articles

United States county jail treatment and care of pregnant incarcerated persons with opioid use disorder.

Benck K, Seide K, Jones A, Omori M, Brinkley Rubinstein L, Beckwith C Drug Alcohol Depend. 2023; 247:109863.

PMID: 37071946 PMC: 10198943. DOI: 10.1016/j.drugalcdep.2023.109863.

Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder.

Kanervo M, Tupola S, Nikkola E, Rantakari K, Kahila H Acta Obstet Gynecol Scand. 2022; 102(3):313-322.

PMID: 36562462 PMC: 9951318. DOI: 10.1111/aogs.14497.

Advancing preventive interventions for pregnant women who are opioid using via the integration of addiction and mental health research.

Mackiewicz Seghete K, Graham A, Shank T, Alsup S, Fisher P, Wilson A Curr Addict Rep. 2020; 7(1):61-67.

PMID: 32201680 PMC: 7083585. DOI: 10.1007/s40429-020-00296-x.

Long-term treatment retention in West Virginia's comprehensive opioid addiction treatment (COAT) program.

Lander L, Zheng W, Hustead J, Mahoney 3rd J, Berry J, Marshalek P J Neurol Sci. 2020; 411:116712.

PMID: 32058182 PMC: 7409552. DOI: 10.1016/j.jns.2020.116712.

West Virginia's model of buprenorphine expansion: Preliminary results.

Winstanley E, Lander L, Berry J, Mahoney 3rd J, Zheng W, Herschler J J Subst Abuse Treat. 2019; 108:40-47.

PMID: 31221524 PMC: 7055678. DOI: 10.1016/j.jsat.2019.05.005.

References

Colombini N, Elias R, Busuttil M, Dubuc M, Einaudi M, Bues-Charbit M . Hospital morphine preparation for abstinence syndrome in newborns exposed to buprenorphine or methadone. Pharm World Sci. 2007; 30(3):227-34. DOI: 10.1007/s11096-007-9176-1. View

Debelak K, Morrone W, OGrady K, Jones H . Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict. 2013; 22(3):252-4. DOI: 10.1111/j.1521-0391.2012.12005.x. View

Jones H, OGrady K, Malfi D, Tuten M . Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict. 2008; 17(5):372-86. DOI: 10.1080/10550490802266276. View

Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S . Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend. 2005; 82(3):250-7. DOI: 10.1016/j.drugalcdep.2005.10.001. View

Whitham J, Spurrier N, Sawyer M, Baghurst P, Taplin J, White J . The effects of prenatal exposure to buprenorphine or methadone on infant visual evoked potentials. Neurotoxicol Teratol. 2009; 32(2):280-8. DOI: 10.1016/j.ntt.2009.09.001. View

Fudala P, Bridge T, Herbert S, Williford W, Chiang C, Jones K . Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003; 349(10):949-58. DOI: 10.1056/NEJMoa022164. View

Jones H, Kaltenbach K, Heil S, Stine S, Coyle M, Arria A . Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010; 363(24):2320-31. PMC: 3073631. DOI: 10.1056/NEJMoa1005359. View

Kakko J, Heilig M, Sarman I . Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008; 96(1-2):69-78. DOI: 10.1016/j.drugalcdep.2008.01.025. View

Strain E, Harrison J, Bigelow G . Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. Clin Pharmacol Ther. 2011; 89(3):443-9. PMC: 3225026. DOI: 10.1038/clpt.2010.352. View

10.

Metz V, Jagsch R, Ebner N, Wurzl J, Pribasnig A, Aschauer C . Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women. Hum Psychopharmacol. 2011; 26(6):412-21. PMC: 5494260. DOI: 10.1002/hup.1224. View

11.

Brunton P, Meddle S, Ma S, Ochedalski T, Douglas A, Russell J . Endogenous opioids and attenuated hypothalamic-pituitary-adrenal axis responses to immune challenge in pregnant rats. J Neurosci. 2005; 25(21):5117-26. PMC: 6724825. DOI: 10.1523/JNEUROSCI.0866-05.2005. View

12.

Douglas A, Meddle S, Toschi N, Bosch O, Neumann I . Reduced activity of the noradrenergic system in the paraventricular nucleus at the end of pregnancy: implications for stress hyporesponsiveness. J Neuroendocrinol. 2005; 17(1):40-8. DOI: 10.1111/j.1365-2826.2005.01272.x. View

13.

Jones H, Johnson R, Jasinski D, OGrady K, Chisholm C, Choo R . Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005; 79(1):1-10. DOI: 10.1016/j.drugalcdep.2004.11.013. View

14.

Johnson R, Jones H, Fischer G . Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend. 2003; 70(2 Suppl):S87-101. DOI: 10.1016/s0376-8716(03)00062-0. View

15.

Schindler S, Eder H, Ortner R, Rohrmeister K, Langer M, Fischer G . Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction. 2002; 98(1):103-10. DOI: 10.1046/j.1360-0443.2003.00245.x. View

16.

Fischer G, Johnson R, Eder H, Jagsch R, Peternell A, Weninger M . Treatment of opioid-dependent pregnant women with buprenorphine. Addiction. 2000; 95(2):239-44. DOI: 10.1046/j.1360-0443.2000.95223910.x. View

17.

Jones H, Kaltenbach K, Heil S, Stine S, Coyle M, Arria A . Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus?. J Matern Fetal Neonatal Med. 2012; 25(7):1197-201. DOI: 10.3109/14767058.2011.653423. View

18.

Binder T, Vavrinkova B . Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up.... Neuro Endocrinol Lett. 2008; 29(1):80-6. View

19.

Kaltenbach K, Berghella V, Finnegan L . Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am. 1998; 25(1):139-51. DOI: 10.1016/s0889-8545(05)70362-4. View

20.

Blinick G . Menstrual function and pregnancy in narcotics addicts treated with methadone. Nature. 1968; 219(5150):180. DOI: 10.1038/219180a0. View